** Shares of biotech firm Creative Medical Technology Holdings CELZ.O rise 16.1% to $5.33 premarket
** Co says its mid-term follow-up data showed its stem cell therapy, called StemSpine, was successful in treating chronic lower back pain and reducing opioid dependency
** Says the study shows significant improvements in pain levels and functional mobility
** Says no serious adverse events were reported
** Over 90% of patients reported no opioid use for pain management three years post-procedure, co says
** CELZ rose ~9% in the last 12 months
(Reporting by Siddhi Mahatole)
((siddhiprabhanjan.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。